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ABSTRACT
Objective: To determine and compare the prevalence of MSH6 (a mismatch repair gene) mutations in a cohort of families with 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC), and in an unselected cohort of endometrial cancer patients (EC).
Design: Two patient cohorts participated in the study. A cohort of HNPCC families who were known to the Regional Medical 
Genetics department, and an unselected cohort of patients with a history of EC.  All participants received genetic counselling on 
the implications of molecular testing, and blood was taken for DNA extraction with consent.  All samples underwent sequencing 
and Multiple Ligation probe analysis (MLPA) for mutations in MSH6. 
Populations: DNA from one hundred and forty-three probands from HNPCC families and 125 patients with EC were included 
in the study. 
Methods: Molecular analysis of DNA in all participants from both cohorts for mutations in MSH6.
Outcome measures: Prevalence of pathogenic mutations in MSH6.
Results: A truncating mutation in MSH6 was identified in 3.8% (95% CI 1.0-9.5%) of patients in the endometrial cancer cohort, 
and 2.6% (95% CI 0.5-7.4%) of patients in the HNPCC cohort.  A missense mutation was identified in 2.9% and 4.4% of the 
same cohorts respectively.  No genomic rearrangements in MSH6 were identified.  
Conclusion: MSH6 mutations are more common in EC patients than HNPCC families.  Genomic rearrangements do not 
contribute to a significant proportion of mutations in MSH6, but missense variants are relatively common and their pathogenicity 
can be uncertain. HNPCC families may be ascertained through an individual presenting with EC, and recognition of these families 
is important so that appropriate cancer surveillance can be put in place.
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InTRODuCTIOn
HNPCC is an autosomal dominant highly penetrant cancer-
susceptibility  syndrome  caused  by  germline  mutations  in 
one  of  the  DNA  mismatch  repair  (MMR)  genes,  namely 
MLH1,  MSH2  and  MSH61.   Affected  individuals  have  a 
predisposition to developing early onset colorectal cancer 
(CRC) and other HNPCC associated cancers, particularly 
endometrial cancer (EC)2.
Diagnosis of HNPCC is dependent on familial clustering of 
CRC’s, and other HNPCC related cancers, early onset cancers, 
and synchronous and metachronous cancers.  Associated with 
a life time cancer risk of up to 80% 3,4, early diagnosis enables 
at risk family members to be enrolled in a cancer surveillance 
programme, thus reducing mortality and morbidity 5-7. 
The Amsterdam criteria, developed in 1991 by the International 
Collaborative Group on Hereditary Non-polyposis Colorectal 
Cancer (ICG-HNPCC)8, and subsequently revised in 19999, 
are not diagnostic, but can be used to standardise HNPCC 
families for comparative multi-centre studies (see Boxes 1 
and 2).   
MLH1 and  MSH2  mutations  account for  the majority  of 
known  mutations  in  HNPCC  families,  and  can  represent 
between  25%10  and  49%  of Amsterdam  criteria  positive 
families11.   Higher mutation detection rates of 86% have been 
published, but this may be as a result of founder mutations12.   
MSH6 mutations were first reported in HNPCC kindreds 
in 199713,14, and are less prevalent in HNPCC cohorts with 
MSH6 mutations estimated to represent approximately 10% © The Ulster Medical Society, 2008.
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of all MMR mutations in HNPCC families15,16.  Between 2-5% 
of HNPCC families including Amsterdam I, Amsterdam II, or 
‘HNPCC like’ will have a germline mutation in MSH615,17,18.   
Mutations  have  been  described  in  PMS2  and  PMS1  in 
HNPCC kindreds but have not been found to contribute to a 
significant proportion of families19,20.
In comparison to MLH1 and MSH2, the phenotype of MSH6 
is characterised by a later age of onset of CRC, incomplete 
penetrance, and a higher risk and later age of onset of EC 
in  female  MSH6  carriers15,21.    MSH6  mutation  carriers 
may be missed amongst analysis of HNPCC families if the 
Amsterdam criteria are used as selection criteria22 It is likely 
that MSH6 mutations may occur at a higher prevalence in 
a cohort of EC patients in comparison to HNPCC cohorts 
that have been selected by the Amsterdam criteria which are 
characteristic of HNPCC families with a mutation in MLH1 
or MSH2.  A few studies have looked at the prevalence of 
MSH6 mutations in EC patients with estimates between 1.7% 
of patients with EC less than 50 years23, and 4.7% identified 
in EC patients un-selected for age or family history24.
In this study we sought to determine the prevalence of MSH6 
mutations in our Northern Ireland HNPCC cohort with less 
restrictive inclusion criteria than the Amsterdam II criteria, in 
an attempt to include as many MSH6 phenotype families as 
possible given the probable later onset of colon cancers; and 
also determine the prevalence of mutations in an unselected 
cohort of EC patients.  
MeThODS
Subject Recruitment 
The study was granted ethical approval by the Office for 
Research Ethics Committees Northern Ireland (ORECNI). 
Two patient cohorts were recruited; HNPCC and endometrial 
cancer patient cohorts.  Sample sizes were calculated from 
previous studies with estimated prevalence figures of MSH6 
of 9%16 and 8%25 respectively in each cohort, giving a target 
size of 197 cases for an estimate of prevalence with 95% 
confidence intervals no wider than +/- 4% for the HNPCC 
cohort  and  a  target  size  of  177  cases  for  an  estimate  of 
prevalence with 95% confidence intervals no wider than +/- 
4% for the endometrial cohort. 
The  HNPCC  cohort  was  known  to  the  regional  genetics 
department, and had received genetic counselling in the past, 
with blood taken for diagnostic testing of MLH1 and MSH2 
or DNA storage.  All families who met the Amsterdam I 
and II criteria were included.  In addition, inclusion criteria 
was extended to families with a clustering of CRC, or other 
HNPCC related cancer, with at least three affected family 
members (age not restricted), or at least two family members if 
the age of onset was below 50 years with pedigrees suggestive 
of autosomal dominant inheritance, or an individual with 
CRC diagnosed less than 35 years – similar to the Bethesda 
criteria.  Probands were contacted with information regarding 
the  study,  and  a  consent  form  with  a  stamped  addressed 
envelope (SAE) to return if they wished to participate.  One 
hundred and forty-three participants in total were recruited to 
this cohort 35 meeting the Amsterdam I, 6 Amsterdam II, and 
102 classified as ‘HNPCC like’. 
Patients  with  a  history  of  EC  (back  to  01/01/99)  were 
identified by means of a pathology coding database covering 
all patients from the Eastern Health Board in Northern Ireland 
and recruited consecutively.  
All potential participants were contacted with a participant 
information sheet, with a detachable reply slip, to be returned 
in  the  enclosed  SAE,  for  those  keen  to  participate.    For 
patients with returned reply slips, a clinic appointment was 
offered to discuss the study with genetic counselling, and 
obtain medical details, family history, informed consent and 
a blood sample for DNA extraction.  One hundred and eighty-
eight potential participants were contacted, and one hundred 
and twenty-five participants were recruited to this cohort.   
Age ranged from twenty-six to eighty-four, with a mean age 
of 58.9 years.  Mean body mass index (BMI) in this cohort 
was 30.65, ranging from 18.64-53.15. 
MSh6 Sequencing
All DNA was or had been extracted by the Nucleic Acid 
Extraction Centre (NAEC), Belfast City Hospital, and stored 
at -80˚C.  Working dilutions in X1 TE were made at 5ng/µl.  
All ten exons and at least 20 base pair (bp) of flanking intronic 
sequence  was  subject  to  direct  sequencing  analysis.    PCR 
products for nine of ten exons of MSH6 were obtained using 
Applied  Biosystems  VariantSEQrTM  Requencing  System 
(product  number:  RSS000012234_02).   All  reactions  were 
carried  out  using  standard  reaction  mix  and  conditions 
as  determined  by ABI.    Exon  1  primers  were  as  follows: 
Bo x  1: 
Amsterdam criteria I
There should be at least three relatives with 
histologically verified CRC; all of the following criteria 
should be present:
One should be a first degree relative of the other two; •	
At least two successive generations should be  •	
affected;
At least one CRC should be diagnosed before age 50; •	
FAP should be excluded in the CRC case; •	
Tumours should be verified by pathological  •	
examination
Bo x  2: 
Amsterdam criteria II
At least three relatives with an HNPCC associated 
cancer *
One affected person is a first degree relative of the  •	
other two
At least two successive generations are affected •	
At least one person was diagnosed before the age of  •	
50 years
Familial adenomatous polyposis has been excluded •	
Tumours have been verified by pathological  •	
examination
*large bowel, endometrium, small bowel, ureter, or renal pelvis, though not 
including stomach ovary, brain, bladder or skin© The Ulster Medical Society, 2008.
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1F  PCR;  TCCGTCCGACAGAACGGTTG,  1R  PCR; 
ATGCTCCAGACTCGACCCG, using a standard 25µl reaction 
mix with 3.4µl of 25mm MgCl2 and 0.4µl of 5U/µl Expand 
DNA polymerase (ABI) at an annealing temperature of 60°C.
All PCR products were subject to clean up using ExoSAP-
IT®† to remove excess primer dimer, unincorporated dNTPs, 
and non-specific DNA products. Sequencing reactions were 
carried out using BigDye® terminator Ready Reaction Mix 
v1.1 from ABI®, according to manufacturer’s instructions.   
Additional  primers  were  required  to  sequence  exons  7 
and 8 because of a poly T at the 5′ end of exon 7, which 
resulted  in  slippage  during  the  sequencing  reaction,  and 
polymorphisms situated at the 3′, (c.3646 +35_38delATCT) 
of exon 7, and 5′, (c.3647 -51_-35 del 17), and 3′ (c.3802-
42insT) end of exon 8, which made sequence of the exons 
unreadable  when  the  polymorphisms  were  present  in 
the  heterozygous  state.    Additional  sequencing  primers 
for  exon  7  (7F  Seq;  TTGTGATTTTTTTTTTTTTAAG, 
7R  Seq;  TAGTCTTCAAATGAGAAG)  and 
8  (8F  Seq;  GAGTTACTTCCTTATGCA  ,  8R  Seq; 
GAAGTGCCCTCTCAAAAAACC)  were  designed.   
Electrophoresis was carried out by the Queen’s University 
Belfast  genomic  core  facility  on  an  ABI  3730  DNA 
analyser.
MLPA Analysis
All samples were subject to MLPA analysis using SALSA 
MLPA  KIT  POO8  MSH6/PMS2  from  MRC-Holland.   
Reaction mix and conditions are as determined by MRC-
Holland.    Electrophoresis  was  carried  on  an  ABI  3100 
Avant DNA analyzer using a GeneScan™ - 500 ROX™ size 
standard.  From the raw data generated, peak heights of each 
amplification  product  were  exported  to  Excel  worksheets 
designed by Dr Andrew Wallace, National Genetics Reference 
Laboratory, Manchester, so that the result of each sample 
could be ‘normalised’.    
Statistical Methods
The  cohort  sizes  necessary  to  obtain  estimates  with 
adequate precision were initially calculated using a Normal 
approximation to the binomial sampling distribution provided 
by the StatCalc program in the EpiInfo package (http://www.
cdc.gov/EpiInfo/). The Stata package (http://www.stata.com) 
was used to give the exact binomial confidence limits for a 
proportion (Table I).  
ReSuLTS
MSh6
Good  quality  sequence  was  obtained  for  all  10  exons  of 
MSH6 in 220 participants, 115 from HNPCC cohort, and 
105 from endometrial cohort.  Results with exact binomial 
confidence limits for a proportion are shown in table I.  Given 
that the pathogenicity of the missense mutations identified has 
yet to be determined, arguably the proportion of the truncating 
mutations is more relevant.
All sequences were viewed with reference to a control sample 
(with a known mutation in MLH1 or MSH2), and reference 
sequences (www.ensemble.org, www.ncbi.nlm.nih.gov). All 
variants are described with reference to den Dunnen et al26.
Ta B l e  I: 
Number of mutations identified in each cohort
HNPCC  (115)   95% CI Endometrial (105) 95% CI Total 220 
Truncating 3 (2.6%)  0.5% - 7.4% 4 (3.8%)  1.0% - 9.5% 7 (3.2%) 
Missense 5 (4.4%)  3 (2.9%)  8 (3.6%) 
Total 8 (7.0%)   3.1% - 13.2% 7 (6.7%)  2.7% - 13.3% 15 (6.8%) 
Ta B l e  II: 
Truncating mutations identified
Nucleotide Change Protein Change Mutation  Exon Cohort Classification
c.642 C>A (p.Tyr214X) Truncating 4 HNPCC HNPCC like
c.755 C>G (figure 1) (p.Ser252X) Truncating 4 EC HNPCC like
c.755 C>G (p.Ser252X) Truncating 4 EC Not HNPCC
c.3103 C>T (p.Arg1035X) Truncating 4 EC HNPCC like
c.3261 delC (p.Pro1087Pro fs X3) Truncating 5 HNPCC HNPCC like 
c.3840_3846delGGAGACT (p.Gln1280_Thr1282>GlnfsX45) Truncating 9 HNPCC HNPCC like
c.3938_3941dupTTCA (p.Gln1314HisfsX14) Truncating 9 EC Amsterdam II
Fig 1. Sequencing analysis showing a truncating mutation c.755 
C>G (p.Ser252X) in exon 4 of MSH6© The Ulster Medical Society, 2008.
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All truncating and missense variants identified are shown in 
tables II and III (example figure 1) with their corresponding 
cohort  and  family  classification.    Participants  from  the 
endometrial  cohort  with  a  variant  identified  were  also 
classified according to Amsterdam I, II, ‘HNPCC like’, or, 
a family history that was not in keeping with HNPCC.  All 
missense variants were subject to analysis by PolyPhen (www.
coot.embl.de/PolyPhen/), a tool that predicts the potential 
impact of an amino acid substitution on the structure and 
function of a human protein (see table III for predictions). 
Further population, family and functional studies were not 
carried out to evaluate the missense variants but further work 
is planned.
MLPA
All samples underwent MLPA analysis. Out of 268 successful 
MLPA results, no aberration in copy number was identified.
DISCuSSIOn 
Fifteen variants in all were identified from the two cohorts, 
seven of which resulted in premature STOP codon (truncating 
mutations), and were therefore considered pathogenic.  A 
further eight missense mutations were identified, of which the 
functional significance is not known at this time.  A summary 
of results is shown in table I. At the time of study design, only 
estimates of total prevalence were available16,25 and the cohort 
sizes actually attained in the study were smaller than planned.   
This is reflected in lower precision (wider confidence limits) 
in the estimates than had originally been specified.  
hnPCC Cohort
A definite pathogenic mutation was identified in 2.6% of the 
HNPCC cohort.  These results are comparable with other 
studies carried out on Amsterdam, Amsterdam II and ‘HNPCC 
like’ families – estimates range between 2% and 5% - who 
have a germline mutation in MSH615,17,18.  Further work on the 
missense variants is required to determine their pathogenicity, 
as the yield of MSH6 mutations in the HNPCC cohort could 
increase up to 7% if these are found to be significant.  
endometrial cohort
A truncating germline mutation was identified in 3.8% of 
the endometrial cohort.  This is higher than that obtained 
for the HNPCC cohort of whom the majority were ‘HNPCC 
like’, thereby broadening the criteria to fit with the described 
characteristics of a MSH6 phenotype15,21.  This prevalence 
figure  is  also  likely  to  increase  following  further  work 
(including immunohistochemistry), being carried out on the 
missense variants as some of these may be pathogenic. 
There are few studies looking at MSH6 in EC.  Comparison 
can be difficult to make between studies because of pre-
selection  of  some  study  groups  of  EC  patients  by  age 
restriction or tumour microsatellite instability. Goodfellow26 
estimated  the  minimum  prevalence  of  inherited  MSH6 
mutations in EC to be 1.6%, from a sub-population of an 
EC cohort, selected for molecular analysis, the majority of 
which showed tumour microsatellite instability (MSI).  A 
comparable figure is seen by Berends23 one MSH6 mutation 
identified in a cohort of 58 EC patients diagnosed less than 
50 years whose families fulfilled the Amsterdam II criteria.   
Higher figures of 4.7%24, and 8.3%25, have been observed 
in EC cohorts not restricted by age or the limitations of the 
Amsterdam II criteria, but where the majority of tumours 
exhibit MSI, although the significance of the latter study will 
be limited by its relatively small cohort.  
As  well  as  the  heterogeneous  populations  studied,  the 
variability in frequency of MSH6 mutations in both HNPCC 
and endometrial cohorts can also be accounted for by the 
sensitivity of techniques used to identify variants, the use 
of  MSI  and  IHC  to  target  molecular  screening  of  MMR 
genes, and the interpretation of missense mutations which 
occur relatively frequently in MSH623.  Founder mutations 
in  certain  populations  can  also  contribute  to  higher  than 
average prevalence rates of MMR genes12.  Further work 
on functional, population and family studies is required to 
determine the pathogenicity of the eight missense mutations 
identified.  
Genomic Rearrangements
Genomic rearrangements account for between 17%28 to 54.8% 
of pathogenic mutations in MLH1 and MSH2 in HNPCC 
families29.  The prevalence of genomic rearrangements in 
MSH6 is less well studied, but it had been estimated that 
rearrangements  may  account  for  10-20%  of  mutations  in 
MSH630. No genomic rearrangements were identified in our 
HNPCC cohort consistent with findings by Charbonnier31and 
Wagner18.      Likewise  genomic  rearrangements  were  not 
detected in any of our EC patients in keeping with findings 
by Ollikaninen32.  Studies that have identified MSH6 genomic 
rearrangements  have  been  particularly  large  HNPCC 
Ta B l e  III:  
Missense variants identified
Nucleotide Change Protein Change Polyphen prediction Exon Cohort Classification
c.663 A>C (p.Glu221Asp)  Benign 4 EC HNPCC like
[c.866 G>A]+[c.867C>A] [p.Gly289Asp]+[p.Gly289Gly].  Benign 4 HNPCC HNPCC like
c.1508 C>G (p.Ser503Cys)  Possibly damaging 4 HNPCC Amsterdam I
c.1508 C>G (p.Ser503Cys)  Possibly damaging 4 EC Not HNPCC
c.1739 C>T (p.Ser580Leu)  probably damaging 4 HNPCC HNPCC like
c.3217 C>T (p.Pro1073Ser)  Benign 5 HNPCC Amsterdam II
c.3929 G>C (p.Glu1310Asp)  Benign 9 HNPCC HNPCC like
c.3963 A>T (p.Arg1321Ser)  possibly damaging 9 EC HNPCC like© The Ulster Medical Society, 2008.
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cohorts33, or EC cohorts pre-selected by MSI24, yielding a 
genomic rearrangement in MSH6 in less than 1% of the 
chosen population.  
Promoter Region 
Sequencing is highly sensitive for detection of mutations in 
the coding regions; however the promoter region of MSH6 
was not sequenced in this study.  
Previous studies have mainly concentrated on coding regions, 
and exonic / intronic boundaries.  Two deletions of the MSH6 
promoter region have been described in HNPCC families22,33, 
but other studies looking at the promoter region of MSH6 in 
EC cohorts27 or in HNPCC patients negative for a mutation in 
MLH1 or MSH217, did not identify any pathogenic mutations.   
Studies looking specifically at the promoter region of the 
more prevalent MMR genes, MLH1 and MSH2, identified 
three possible pathogenic mutations in the promoter area in 
141 HNPCC patients and patients with early onset CRC (<45 
years)34.  Given that MSH6 mutations occur at a relatively 
low rate in both HNPCC and EC patients, we can assume that 
mutations of the promoter region in either cohort are unlikely 
to significantly alter the prevalence figures calculated from 
this study.  
Redundancy of MSh6 mutations
Although  germline  mutations  in  MSH6  are  distributed 
throughout the length of MSH6 displaying little redundancy, 
the majority of pathogenic mutations identified are in exon 
415, with fifty-seven percent of truncating mutations identified 
in this study (4/7) occurring in exon 4, the largest of MSH6 
exons, indicating that analysis of MSH6 in HNPCC families 
without a known mutation should commence at exon 4.   
MSh6 phenotype
None  of  the  truncating  mutations  identified  in  this  study 
met the original Amsterdam criteria, the majority having a 
‘HNPCC like’ phenotype, with a later age of cancer onset, and 
non-penetrance in family members (Table IV).  This further 
supports current evidence that application of the Amsterdam 
criteria to HNPCC families to select for molecular testing 
will result in a significant proportion of MSH6 mutations 
being missed15,22.
Previously unidentified hnPCC families
Eighteen out of 125 participants (14.4%) from the endometrial 
cohort  had  a  significant  previously  unidentified  HNPCC 
phenotype. Five of these participants had a variant identified, 
three  truncating  mutations  and  two  missense  mutations. 
These  findings  are  in  keeping  with  findings  from  other 
studies where previously unidentified HNPCC families have 
been ascertained through an individual with EC23. Increased 
awareness of HNPCC and other hereditary cancer syndromes 
amongst  physicians/surgeons  directly  involved  with  the 
care  of  cancer  patients  such  as  gynaecologists,  surgeons, 
oncologists, and general practitioners is essential for their 
identification.
endometrial Cancer
HNPCC, traditionally identified as a condition with a genetic 
predisposition to CRC, has now been recognised as conferring 
a significant risk of EC to females, particularly those with a 
mutation in MSH6. In addition to other Mendelian inherited 
syndromes with a predisposition to EC such as Muir Torré, 
Cowden and Turcot syndrome, there are families who show 
a  clustering  of  EC  alone  that  do  not  have  an  identifiable 
molecular  basis.  Un-identified  genes  or  predisposing  low 
penetrant polymorphisms may contribute. The importance of 
environmental factors conferring a risk to the development 
of EC cannot be underestimated.  Obesity is associated with 
increased levels of endogenous oestrogens, and is a significant 
risk  factor  for  the  development  of  EC.  Mean  BMI  in  the 
endometrial cohort was 30.65 and ranged from 18.64-53.15, 
with only 28 (22.4%) of participants having a BMI within the 
normal range (<25). In comparison it is estimated that 44% of 
UK females over 16 years have a BMI within the normal range. 
(Figures published by the Department of Health and estimated 
by the Health Survey for England 2003; www.dh.gov.uk).
The mean BMI for the four participants from the endometrial 
cohort with a truncating mutation in MSH6 was 26.2, ranging 
from 22.36-31.05. One of these participants had a BMI in the 
overweight range, and one had a BMI in the obese range.  It is 
likely that obesity has an additive effect to the underlying risk 
form a MMR mutation, but larger studies would be required 
to determine this.  
COnCLuSIOn
From this study we have identified the minimum prevalence of 
pathogenic mutations in MSH6 to be higher in an unselected 
cohort of EC patients, than a cohort of HNPCC patients who 
have been selected by criteria ‘widened’ from the traditional 
Amsterdam  II  criteria,  in  keeping  with  the  described 
phenotype of MSH6.  Unlike the other more common MMR 
genes, genomic rearrangements do not contribute to a large 
proportion of mutations in MSH6. 
HNPCC families may not be identified if patients present 
with  HNPCC  associated  cancers,  such  as  gynaecological 
cancer, rather than the more commonly recognised phenotype 
of  CRC.  Clinicians  should  be  vigilant  to  this  possibility 
when  presented  with  a  history  of  endometrial  cancer  in 
young women. Further work on immunohistochemistry of 
possible missense variants may increase the true frequency 
of mutations in MSH6.
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Ta B l e  IV: 
Classification of families with a MSH6 variant identified
Truncating Missense
Amsterdam I 0 1
Amsterdam II 1 1
‘HNPCC like’ 5 5
Not HNPCC 1 1© The Ulster Medical Society, 2008.
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